诱导化疗后18F-FDG PET反应可预测食管腺癌放化疗后哪些患者可从后续食管切除术中获益
本研究分析了220例接受诱导化疗后同步放化疗(联合或不联合手术)的食管腺癌患者,所有患者均在诱导化疗前后接受18F-FDG PET扫描。诱导化疗后18F-FDG PET完全缓解(最大SUV≤3.0)与双模式治疗患者的生存相关,并可预测三模式治疗患者的病理反应。在18F-FDG PET无反应者中,三模式治疗较双模式治疗显著改善生存;而在有反应者中,两种治疗模式的生存相似。作者认为18F-FDG PET反应可能是有用的影像生物标志物,但需前瞻性验证。
要点
- 诱导化疗后18F-FDG PET完全缓解(最大SUV≤3.0)可预测食管腺癌患者的生存及病理反应。
- 在18F-FDG PET无反应者中,三模式治疗较双模式治疗显著改善生存(P<0.001)。
- 在18F-FDG PET有反应者中,双模式与三模式治疗的生存相似。
核心结论
- 诱导化疗后的18F-FDG PET反应可能是有用的影像生物标志物,用于识别可从放化疗后后续食管切除术中获益的食管腺癌患者。
- 与双模式治疗相比,三模式治疗可显著改善18F-FDG PET无反应者的生存。
- 然而,18F-FDG PET有反应者接受双模式或三模式治疗后的结局相似。
- 作者指出需要对这些发现进行前瞻性验证。
研究设计与样本
- 研究识别并分析了220例接受诱导化疗后放化疗(联合或不联合手术)的食管腺癌患者,所有患者均在诱导化疗前后接受18F-FDG PET扫描。
- 18F-FDG PET有反应者定义为诱导化疗后达到完全缓解(最大SUV≤3.0)的患者。
- 86例患者接受双模式治疗(BMT;诱导化疗+放化疗),134例接受三模式治疗(TMT;诱导化疗+放化疗联合手术)。
主要发现
- 48例患者(21.8%)在诱导化疗后达到18F-FDG PET完全缓解。
- 在BMT患者中,18F-FDG PET完全缓解与总生存(OS)和无进展生存(PFS)相关。
- 在TMT患者中,18F-FDG PET完全缓解可预测病理反应(P=0.003),但未预测生存。
- 在18F-FDG PET无反应者中,TMT患者生存显著优于BMT患者(P<0.001)。
- 在18F-FDG PET有反应者中,BMT患者的总生存(P=0.201)和无进展生存(P=0.269)与TMT患者相似。
关键数值与推荐
- 18F-FDG PET完全缓解定义为诱导化疗后最大SUV≤3.0。
- 在TMT患者中,18F-FDG PET完全缓解预测病理反应(P=0.003)。
- 在18F-FDG PET无反应者中,TMT较BMT显著改善生存(P<0.001)。
- 在18F-FDG PET有反应者中,BMT与TMT的总生存比较P=0.201,无进展生存比较P=0.269。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出需要对这些发现进行前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study aimed to determine whether 18F-FDG PET response after induction chemotherapy before concurrent chemoradiotherapy can identify patients with esophageal adenocarcinoma who may benefit from subsequent esophagectomy. Methods: We identified and analyzed 220 patients with esophageal adenocarcinoma who had received induction chemotherapy before chemoradiotherapy, with or without surgery, with curative intent; all underwent 18F-FDG PET scanning before and after induction chemotherapy. 18F-FDG PET responders were defined as patients who achieved complete response (CR) after induction chemotherapy (maximum SUV ≤ 3.0). The predictive value of 18F-FDG PET response for patient outcomes was evaluated. Results: Overall, 86 patients had bimodality therapy (BMT; induction chemotherapy + chemoradiotherapy) and 134 had trimodality therapy (TMT; induction chemotherapy + chemoradiotherapy with surgery). Forty-eight patients (21.8%) achieved an 18F-FDG PET CR after induction chemotherapy. 18F-FDG PET CR was found to correlate with overall survival (OS) and progression-free survival (PFS) in BMT patients. For TMT patients, 18F-FDG PET CR predicted pathologic response (P = 0.003) but not survival. Among 18F-FDG PET nonresponders, TMT patients had significantly better survival than did BMT patients (P < 0.001). However, among 18F-FDG PET responders, BMT patients had OS (P = 0.201) and PFS (P = 0.269) similar to that of TMT patients. After propensity score-matched analysis, 18F-FDG PET responders treated with BMT versus TMT still had comparable OS and PFS, but TMT was associated with better locoregional control. Conclusion:18F-FDG PET response to induction chemotherapy could be a useful imaging biomarker to identify patients with esophageal adenocarcinoma who could benefit from subsequent esophagectomy after chemoradiotherapy. Compared with BMT, TMT can significantly improve survival in 18F-FDG PET nonresponders. However, outcomes for 18F-FDG PET responders were similar after either treatment (BMT or TMT). Prospective validation of these findings is warranted.
引用
- Xi M, Liao Z, Hofstetter WL, et al. 18F-FDG PET Response After Induction Chemotherapy Can Predict Who Will Benefit from Subsequent Esophagectomy After Chemoradiotherapy for Esophageal Adenocarcinoma. J Nucl Med. 2017. PMID: 28522744. doi:10.2967/jnumed.117.192591
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。